Stay updated with breaking news from Jack Khattar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The drug/device combination therapy provides a continuous subcutaneous infusion of apomorphine through an infusion pump. The FDA has issued a Complete Response Letter to Supernus Pharmaceuticals regarding the New Drug Application for SPN-830.
ROCKVILLE, Md., April 08, 2024 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...
The drug/device combination therapy provides a continuous subcutaneous infusion of apomorphine through an infusion pump. The FDA has issued a Complete Response Letter to Supernus Pharmaceuticals regarding the New Drug Application for SPN-830.
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
ROCKVILLE, Md., Feb. 28, 2024 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...